Research programme: VCAM/VLA-4 inhibitors - Kaken

Drug Profile

Research programme: VCAM/VLA-4 inhibitors - Kaken

Alternative Names: Cell adhesion inhibitors research programme - Kaken; Research programme: cell adhesion inhibitors - Kaken; VCAM/VLA-4 antagonists research programme - Kaken

Latest Information Update: 24 Feb 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kaken Pharmaceutical
  • Class
  • Mechanism of Action Integrin alpha4beta1 antagonists; Vascular cell adhesion molecule inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Inflammation

Most Recent Events

  • 02 Sep 2004 This programme is still in active development
  • 28 May 2001 Preclinical development for Asthma in Japan (Unknown route)
  • 28 May 2001 Preclinical development for Inflammation in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top